Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yun Lu has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Regulatory Interventions for Package Inserts and Patient Medication Information: A Systematic Review

    by Wantong Yang, Linning Wang, Yun Lu, Feng Chang

    Background/Objectives: Package inserts and patient medication information aim to translate complex evidence into practical instructions for safer use. Regulators have standardized content, format, user testing, risk wording, and distribution, but effects along the pathway from readability to medication safety remain unclear. Methods: We searched PubMed/MEDLINE, Embase, Web of Science, Scopus, regulator websites, and citations up to 23 July 2026. Eligible reports evaluated a mandated or endorsed requirement, template, wording, testing process, distribution program, or named initiative. Two reviewers independently screened, assessed full texts, extracted data, and judged methodological quality, resolving disagreements by consensus. Results: Of 2817 records, 34 full texts were assessed, 6 excluded, and 28 reports (27 studies) included. Due to heterogeneity, we synthesized descriptively using an intervention–outcome framework. Standardized structure, user-centered redesign, numerical risk formats, and performance-based testing were generally associated with better information finding and comprehension. Verbal descriptors like “common” or “rare” produced higher perceived probabilities than numerical formats. Large US studies of Medication Guides and consumer information documented excessive length, high reading levels, incomplete objective comprehension, inconsistent distribution quality, and limited risk knowledge. Overall test performance sometimes masked failures in emergency sequencing, contraindications, or applicability. Evidence for adherence, errors, adverse events, and healthcare utilization remained sparse. Conclusions: The findings support prioritized core structure, plain language, numerical risk communication, target-user testing, delivery verification, accessible formats, and post-implementation monitoring. Benefits are best established for proximal communication outcomes; effects on real-world safety remain uncertain.

  • Open Access

    Multidimensional health poverty among diabetic adults in China: evidence from the China Kadoorie Biobank

    by Yanyan Tan, Mengyuan Zhou, Yuwei Bai, Feng Chang, Yun Lu, Yumei Zhu

    Despite the rising burden of diabetes in low- and middle-income countries, conventional economic metrics often fail to capture the multidimensional nature

  • Open Access

    Patient, Physician, and Caregiver Preferences for Lung Cancer Treatment: A Systematic Review of Discrete Choice Experiments

    by Sida Wang, Yun Liu, Mengyu Yang, Linning Wang, Jie Yu, Xiaoxi Xie, Feng Chang, Yun Lu

    Objectives: This systematic review aimed to synthesize evidence from discrete choice experiments to explore the preferences of patients, physicians, and caregivers regarding lung cancer treatment. Methods: A systematic literature search was conducted utilizing the PubMed, Web of Science, Embase, and Scopus databases, encompassing publications up to 12 July 2024. We included published discrete choice experiment (DCE) studies that assessed preferences for lung cancer treatment among patients, physicians, or caregivers, with no restrictions on country, language, publication date, or disease stage. Two researchers independently conducted the literature screening and data extraction. The included studies were assessed for quality using the PREFS checklist. Results: Among the 1086 studies identified, 18 studies met the eligibility criteria. A total of 115 attributes were extracted and categorized into three main categories: outcome, process, and cost, with subcategories under each. Regarding the relative importance of attributes, heterogeneity was observed among stakeholders. The PREFS scores of the 18 included studies, with an average score of 3.8, reflect the high overall quality of these studies. Conclusions: This review revealed both commonalities and differences in lung cancer treatment preferences among patients, physicians, and caregivers. However, existing studies have certain limitations in the coverage of study populations, the scope of attributes, and the research design of the experiments.


  • Open Access

    Health utility values associated with pharmaceutical treatment process attributes: a systematic review and meta-analysis

    by Yun Liu, Xinyu Du, Zheng Rong, Zhen Guo, Feng Chang, Yun Lu, Zhanjing Dai, Yuqiong Lu

    In cases where clinical efficacy and safety profiles are similar, patient preferences for the treatment process become a critical determinant of therapeuti

  • Open Access

    Bidirectional intergenerational support and mental health in older adults based on latent profile analysis: a moderated mediation model

    by Ao Li, Xiaoxi Xie, Xinyang Wan, Zhanjing Dai, Feng Chang, Yun Lu

    Background: Bidirectional intergenerational support is linked to late-life mental health, yet the underlying mechanisms remain unclear. Guided by intergenerational solidarity and social support theories, we examined how distinct support profiles relate to mental health among Chinese older adults, testing self-rated health (SRH) as a mediator and social participation as a moderator. Methods: We analyzed 7,843 adults aged ≥60 from the 2020 China Longitudinal Aging Social Survey. Latent profile analysis (LPA) identified bidirectional support profiles; group differences in mental health were assessed using the Bolck-Croon-Hagenaars (BCH) approach, followed by mediation and moderated-mediation models with bootstrap inference (5,000 resamples). Results: Four profiles emerged—High Support-High Interaction-High Closeness (HS-HI-HC; 47.02%), Child-High Support-Low Interaction-High Closeness (CS-LI-HC; 33.46%), Moderate Support-Moderate Interaction-Low Closeness (MS-MI-LC; 10.37%), and Low Support-Low Interaction-Moderate Closeness (LS-LI-MC; 9.16%). Mental health differed across different profiles, with HS-HI-HC showing the best mental health levels (the lowest scores). SRH partially mediated these associations (for instance, HS-HI-HC indirect effect = −0.186, 95% CI -0.245 to −0.131). Social participation attenuated benefits of high family support but buffered risks under low support. Conclusion: Bidirectional intergenerational support is heterogeneous in China; profiles characterized by reciprocity and closeness show the most favorable mental health. SRH accounts for a modest but meaningful share of these associations, and social participation can substitute for—or amplify—the benefits of family support depending on profile. Findings inform profile-tailored community and family interventions to promote healthy aging.

  • Open Access

    Cost-effectiveness of edaravone dexborneol sublingual tablet versus concentrated solution for injection for the treatment of acute ischemic stroke in China

    by Fan Xie, Yuqiong Lu, Zhuo Yang, Yanlei Zhang, Yujin Bao, Yun Lu

    Background: Edaravone dexborneol sublingual tablet (EDSL) is a novel therapy for acute ischemic stroke (AIS), proven effective and safe. Its convenient dosage form also provides an alternative administration option, helping to enhance treatment accessibility. This study evaluates the cost-effectiveness of EDSL versus edaravone dexborneol concentrated solution for injection (EDCSI) from the Chinese healthcare system perspective. Methods: A combination of the short-term decision tree and long-term Markov model was constructed. Clinical data were derived from the TASTE-SL and TASTE trials. To adjust for baseline characteristics between the two treatment groups, stabilized inverse probability of treatment weighting (sIPTW) was applied, and both Average Treatment effect on the Treated (ATT) and Average Treatment Effect (ATE) weighted results were calculated to enhance comparability. Model parameters were extracted from published literature, public databases, and expert interviews. Sensitivity and scenario analyses were conducted to demonstrate the robustness of the base-case results. Results: There was no statistically significant difference in the proportion of patients achieving mRS score ≤1 between the EDSL and EDCSI groups after sIPTW (ATT: 71.8% vs. 67.6%; ATE: 69.3% vs. 64.6%). Notably, EDSL showed clear cost-effectiveness advantages, with an incremental cost-effectiveness ratio (ICER) of -¥2,089.84 per QALY gained. All sensitivity and scenario analyses confirmed the robustness of the base-case findings. Conclusion: EDSL represents a more cost-effective therapy for AIS patients compared to EDCSI, offering comparable efficacy at a lower drug cost. A full 14-day treatment course may help maximize patient benefits.


  • Open Access

    Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China

    by Wanjie Zhang, Yuqiong Lu, Zhanjing Dai, Linning Wang, Yang Zhou, Yun Lu, Feng Chang

    Background: The recently completed INSPIRE trial demonstrated that iruplinalkib improved progression-free survival and intracranial antitumor activity compared with crizotinib in patients with anaplastic lymphoma kinase (ALK) -positive non-small-cell lung cancer (NSCLC). The objective of this study was to determine the potential cost-effectiveness of iruplinalkib vs. crizotinib in the Chinese healthcare setting.Methods: A cost-effectiveness model was developed using the partition survival method, with three health states: progression-free survival, progressive disease, and death. Data from the INSPIRE trial were used to estimate progression-free and overall survival. Costs included drug treatment, disease management, and adverse events management. Drug costs and utilities were the main drivers of the model in the deterministic sensitivity analysis.Results: Treatment with iruplinalkib versus crizotinib resulted in a gain of 0.55 life-years, 2.11 quality-adjusted life-years (QALYs), and an incremental cost of $4,325.55, resulting in an incremental cost-effectiveness ratio of $2,048.03/QALY. Drug costs and utilities were the main drivers of the model in the deterministic sensitivity analysis. From the probabilistic sensitivity analysis (PSA), iruplinalkib had a 100% probability of being cost-effective at a willingness-to-pay threshold of $13,447.89/QALY.Conclusion: Compared to crizotinib, iruplinalkib is a cost-effective therapy for treatment-naïve patients with ALK-positive NSCLC.

  • Open Access

    Economic evaluations of RSV preventive strategies: a systematic review of cost-effectiveness and modeling approaches

    by Bingde Zhu, Yuqiong Lu, Yang Zhou, Weixiao Li, Yuhang Wu, Yujin Bao, Yun Lu

    Background: Respiratory syncytial virus (RSV) causes significant morbidity and mortality worldwide, particularly in high-risk groups. Despite the availability of preventive interventions, it is crucial to evaluate the economic benefits of these interventions.Methods: This systematic review assessed the cost-effectiveness and model structures of RSV prevention strategies, including vaccines and monoclonal antibodies, by analyzing studies published up to March 2025.Results: A total of 39 studies were included, comprising one cost–benefit analysis (CBA) and 38 cost–effectiveness analyses (CEAs), utilizing six different types of economic models. The incremental cost-effectiveness ratio (ICER) among the older adult population varied from $5,342 to $385,829 per quality-adjusted life year (QALY). One study demonstrated superior cost-effectiveness of a long-acting monoclonal antibody (LAMA) compared to a short-acting monoclonal antibody, with both being more economically favorable than maternal vaccines for pregnant women and neonates. The most sensitive variables were intervention efficacy, price, and immunity duration.Conclusion: Most RSV vaccines and monoclonal antibody interventions demonstrate cost-effectiveness in specific populations and settings. However, cost-effectiveness is highly influenced by intervention price, efficacy, duration, populations, and administration time.Systematic review registration: The protocol for this study has been registered with PROSPERO under the registration number CRD42024524720.


  • Open Access

    Network meta-analysis and cost-effectiveness analysis comparing Cetuximab-β and Cetuximab for Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer

    by Rongjun Tong, Mengyu Yang, Wanjie Zhang, Mengyuan Zhou, Linning Wang, Yun Lu, Feng Chang

    Background: The escalating economic burden of metastatic colorectal cancer (mCRC) in China necessitates cost-effective first-line treatments. Cetuximab-β, a newer version of Cetuximab, is approved for first-line RAS/BRAF wild-type mCRC. This study evaluates the cost-effectiveness of Cetuximab-β with FOLFIRI for mCRC patients, comparing it to Cetuximab plus chemotherapy to guide clinical decision-making and policy development.Methods: We conducted a network meta-analysis (NMA) of six randomized controlled trials to compare overall survival (OS), progression-free survival (PFS), and adverse events (AEs). Subsequently, a cost-effectiveness analysis (CEA) was performed using a 10-year partitioned survival model from the Chinese healthcare payer perspective. Costs were standardized to 2024 US dollars ($1 = ¥7.25). Both costs and outcomes were discounted annually at 5%. The model estimated life-years (LYs), quality-adjusted life-years (QALYs), total costs, and incremental cost-effectiveness ratios (ICER). Model uncertainty was evaluated via one-way sensitivity analysis, probabilistic sensitivity analysis, and scenario analyses.Results: The NMA showed comparable efficacy between Cetuximab-β and Cetuximab, with Cetuximab demonstrating an OS HR of 1.10 (95% CI 0.67–1.90) and a PFS HR of 0.94 (95% CI 0.49–1.80) compared with Cetuximab-β, along with a trend towards a more favorable safety profile for Cetuximab-β. CEA showed Cetuximab-β reduced costs by $12,005.54 ($34,996.43 vs. $47,001.97) and gained 0.10 QALYs (1.90 vs. 1.80 QALYs) versus Cetuximab, yielding a dominant ICER (-$120,743/QALY). Sensitivity and scenario analyses confirmed robustness.Conclusion: Cetuximab-β plus FOLFIRI represents a dominant, cost-saving strategy compared to Cetuximab plus chemotherapy for first-line treatment of RAS/BRAF wild-type mCRC in China.